DNA甲基化在肺癌发生及预后中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.03.514

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (3): 514-518.doi: 10.16352/j.issn.1001-6325.2023.03.514

DNA甲基化在肺癌发生及预后中作用的研究进展

薛剑超¹, 王亚东¹, 李博文¹, 刘新宇², 梁乃新^1*, 李单青¹

1.中国医学科学院北京协和医学院北京协和医院胸外科,北京 100730;
2.北京协和医学院临床医学八年制 2016级, 北京 100730

收稿日期:2021-10-25 修回日期:2022-05-07 出版日期:2023-03-05 发布日期:2023-02-27
通讯作者: * pumchnelson@163.com

Research progress on the role of DNA methylation in the occurrence and prognosis of lung cancer

XUE Jianchao¹, WANG Yadong¹, LI Bowen¹, LIU Xinyu², LIANG Naixin^1*, LI Shanqing¹

1. Department of Thoracic Surgery, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730;
2. Grade 2016, Eight-year Program of Clinical Medicine, PUMC, Beijing 100730, China

Received:2021-10-25 Revised:2022-05-07 Online:2023-03-05 Published:2023-02-27
Contact: * pumchnelson@163.com

摘要/Abstract

摘要： 肺癌是中国发病率和病死率第一的肿瘤,早期复发是预后不良的主要原因。现存的预后指标不足以满足临床需要,亟需寻找可靠的预后指标。DNA甲基化是肺癌发生发展中最主要的表观遗传学改变,随着高通量测序技术的进展,其稳定易检测的特质在肺癌患者的预后预测中有着极大的临床应用价值。

关键词: 肺癌, DNA甲基化, 预后, 表观遗传学

Abstract: Lung cancer is a leading cause of cancer-related morbidity and mortality in China. Early recurrence is the main cause of poor prognosis. The existing prognostic indicators are insufficient. Thus, it is urgent to find reliable prognostic indicators. DNA methylation is the most important epigenetic change in the development of lung cancer. With the development of high-throughput sequencing technology, DNA methylation has shown its great clinical value in the prognosis prediction of lung cancer patients due to its stable and detectable features.

Key words: lung cancer, DNA methylation, prognosis, epigenetics

中图分类号:

R734.2

薛剑超, 王亚东, 李博文, 刘新宇, 梁乃新, 李单青. DNA甲基化在肺癌发生及预后中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 514-518.

XUE Jianchao, WANG Yadong, LI Bowen, LIU Xinyu, LIANG Naixin, LI Shanqing. Research progress on the role of DNA methylation in the occurrence and prognosis of lung cancer[J]. Basic & Clinical Medicine, 2023, 43(3): 514-518.

参考文献

[1]Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71: 209-249.
[2]Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. JNCC, 2022, 2: 1-9.
[3]Bird A. DNA methylation patterns and epigenetic memory[J]. Genes Dev, 2002, 16: 6-21.
[4]Brzeziańska E, Dutkowska A, Antczak A. The significance of epigenetic alterations in lung carcinogenesis[J]. Mol Biol Rep, 2013, 40: 309-325.
[5]Shi YX, Sheng DQ, Cheng L, et al. Current landscape of epigenetics in lung cancer: focus on the mechanism and application[J]. J Oncol, 2019. doi: 10.1155/2019/8107318.
[6]Hoang PH, Landi MT. DNA methylation in lung cancer: mechanisms and associations with histological subtypes, molecular alterations, and major epidemiological factors[J]. Cancers (Basel), 2022, 14:961. doi: 10.3390/cancers14040961.
[7]Ehrlich M. DNA methylation in cancer: too much, but also too little[J]. Oncogene, 2002, 21: 5400-5413.
[8]Soozangar N, Sadeghi MR, Jeddi F, et al. Comparison of genome-wide analysis techniques to DNA methylation analysis in human cancer[J]. J Cell Physiol, 2018, 233: 3968-3981.
[9]Duruisseaux M, Esteller M. Lung cancer epigenetics: from knowledge to applications[J]. Semin Cancer Biol, 2018, 51: 116-128.
[10]Peng X, Liu X, Xu L, et al. The mSHOX2 is capable of assessing the therapeutic effect and predicting the prognosis of stage IV lung cancer[J]. J Thorac Dis, 2019, 11: 2458-2469.
[11]Seok Y, Lee WK, Park JY, et al. TGFBI promoter methylation is associated with poor prognosis in lung adenocarcinoma patients[J]. Mol Cells, 2019, 42: 161-165.
[12]Villalba M, Exposito F, Pajares MJ, et al. TMPRSS4: a novel tumor prognostic indicator for the stratification of stage IA tumors and a liquid biopsy biomarker for NSCLC patients[J]. J Clin Med, 2019, 8:2134. doi: 10.3390/jcm8122134.
[13]Dong Y, Huaying S, Danying W, et al. Significance of methylation of FBP1 gene in non-small cell lung cancer[J]. Biomed Res Int, 2018. doi: 10.1155/2018/3726091.
[14]Liu WB, Han F, Huang YS, et al. TMEM196 hypermethylation as a novel diagnostic and prognostic biomarker for lung cancer[J]. Mol Carcinog, 2019, 58: 474-487.
[15]Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, et al. Epigenetic prediction of response to anti-PD-1 treat-ment in non-small-cell lung cancer: a multicentre, retrospective analysis[J]. Lancet Respir Med, 2018, 6: 771-781.
[16]Han Y, Shi K, Zhou SJ, et al. The clinicopathological significance of hMLH1 hypermethylation in non-small-cell lung cancer: a meta-analysis and literature review[J]. Onco Targets Ther, 2016, 9: 5081-5090.
[17]Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer[J]. J Clin Oncol, 2013, 31: 4140-4147.
[18]Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer[J]. N Engl J Med, 2008, 358: 1118-1128.
[19]Zhu Q, Wang J, Zhang Q, et al. Methylation driven genes PMPCAP1, SOWAHC and ZNF454 as potential prognostic biomarkers in lung squamous cell carcinoma[J]. Mol Med Rep, 2020, 21: 1285-1295.
[20]Gao C, Zhuang J, Li H, et al. Exploration of methylation-driven genes for monitoring and prognosis of patients with lung adenocarcinoma[J]. Cancer Cell Int, 2018, 18: 194. doi: 10.1186/s12935-018-0691-z.
[21]Kou W, Li B, Shi Y, et al. High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis[J]. BMC Cancer, 2022, 22: 110. doi: 10.1186/s12885-021-08912-3.
[22]Wang Y, Deng H, Xin S, et al. Prognostic and predictive value of three DNA methylation signatures in lung adenocarcinoma[J]. Front Genet, 2019, 10: 349. doi: 10.3389/fgene.2019.00349.
[23]Luo R, Song J, Xiao X, et al. Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma[J]. Aging (Albany N Y), 2020, 12: 14649-14676.
[24]Koch A, Joosten SC, Feng Z, et al. Analysis of DNA methylation in cancer: location revisited[J]. Nat Rev Clin Oncol, 2018, 15: 459-466.

DNA甲基化在肺癌发生及预后中作用的研究进展

Research progress on the role of DNA methylation in the occurrence and prognosis of lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	谢晓婷, 张雷, 张莉, 董凤, 刘颖, 李光华, 杨兴. ASH2L在幽门螺旋杆菌感染的人胃癌细胞系中的表达及临床意义[J]. 基础医学与临床, 2023, 43(3): 367-373.
[2]	李雨喋, 王宏宇, 韩松, 李俊发. 激活素A通过少突胶质细胞ACVR1C改善缺血性卒中小鼠神经功能的预后[J]. 基础医学与临床, 2023, 43(3): 380-385.
[3]	孙爱华, 赵艳秋, 王继灵. 老年慢性阻塞性肺部疾病急性加重期患者住院死亡的危险因素及预后[J]. 基础医学与临床, 2022, 42(9): 1414-1418.
[4]	谢思安, 陈奕阳, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 张澍田. PTOV1表达水平对结直肠癌患者预后的影响[J]. 基础医学与临床, 2022, 42(8): 1176-1181.
[5]	樊佳赛, 杜艺菲, 许佳颖, 陈思臻, 高永桧, 任景怡. 基于中医证候和机器学习构建慢性心力衰竭中西医结合预后模型[J]. 基础医学与临床, 2022, 42(8): 1169-1175.
[6]	武坤, 聂波, 李云涛, 杨金荣, 程沈菊, 李艳红, 史明霞. 外周血miR-200c水平对移植异基因造血干细胞后急性移植物抗宿主病发生的预测作用[J]. 基础医学与临床, 2022, 42(6): 871-875.
[7]	哈提米汗·买买提, 姑丽克孜·买买提热夏提, 李俞霆, 周常慧, 李榕. CBX7蛋白在宫颈癌中的表达及其临床意义[J]. 基础医学与临床, 2022, 42(5): 721-725.
[8]	苏路瑛, 黄容, 邹定峰, 许富, 李凯, 卢艳, 缪时英, 王琳芳, 宋伟. 多组学分析发现LAMC2是调节泛癌微环境的关键因子[J]. 基础医学与临床, 2022, 42(4): 545-552.
[9]	张健, 张吉炯. LncRNA UNC5B-AS1靶向miR-339-5p调控人肺腺癌细胞系A549增殖和凋亡[J]. 基础医学与临床, 2022, 42(3): 454-460.
[10]	黄容, 张键, 车旭. SLC4A10表达水平对肝癌患者预后的影响[J]. 基础医学与临床, 2022, 42(3): 461-466.
[11]	郑婧婧, 卜宁, 赵钊, 张佳靖, 于慧, 赵宇航. 心肌肥大表观遗传调控的研究进展[J]. 基础医学与临床, 2022, 42(3): 520-524.
[12]	潘瑞丽, 马千惠, 徐燕, 王孟昭, 王素娥, 关玉霞. 希望水平在晚期肺癌患者抑郁状态与心理韧性中的中介效应[J]. 基础医学与临床, 2022, 42(2): 291-295.
[13]	杨晔, 党荣广, 张静, 董超, 宋雪晶. 肺癌组织中lncRNA ZFAS1和hsa-miR-372-3p的表达与患者恶性特征及预后的关系[J]. 基础医学与临床, 2022, 42(12): 1861-1866.
[14]	何邵波, 罗甫花, 蒋传命, 刘选梅. 红景天苷负向调控TACC2表达抑制NSCLC细胞增殖及上皮间充质转化[J]. 基础医学与临床, 2022, 42(11): 1681-1689.
[15]	斯晓燕, 王汉萍, 张力, 王孟昭, 张晓彤. 免疫检查点抑制剂致细胞因子释放综合征1例[J]. 基础医学与临床, 2022, 42(11): 1764-1766.